Back to Search
BARRY ZEITLIN, M.D.
M.D.
Internal Medicine Physician
NPI: 1750363784Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
G15067(CA)
Research & Publications (9)
TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis.
PMID 19372562·Mol Cancer Ther·2009
7-preclinical
Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells.
PMID 19043530·Transl Oncol·2008
8-other
Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.
PMID 18757333·J Clin Oncol·2008
6-review
Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth.
PMID 17942898·Cancer Res·2007
7-preclinical
Level of endothelial cell apoptosis required for a significant decrease in microvessel density.
PMID 17720154·Exp Cell Res·2007
7-preclinical
Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2.
PMID 16951185·Cancer Res·2006
8-other
Activation of iCaspase-9 in neovessels inhibits oral tumor progression.
PMID 16632757·J Dent Res·2006
7-preclinical
Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.
PMID 16360645·Biochem Pharmacol·2006
4-observational
Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines.
PMID 15958549·Cancer Res·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2261 DOUGLAS BLVD
ROSEVILLE, CA 95661 - Phone
- (916) 783-7109
Quick Facts
- NPI
- 1750363784
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 9
Are you this provider?
Claim Your Profile